Europe
The senior leadership team at Israel-based BrainStorm Cell Therapeutics, Inc. has changed with the appointments of two seasoned industry veterans Joseph Petroziello and Susan Ward.
As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
It feels like we’re standing on the edge of a precipice. Despite the ho-hum recent performance of biotech stocks, amazing things are about to happen. And one of the most amazing of all is gene therapy.
Less than a week after floating the idea of offering its experimental ALS therapy NurOwn to patients under the recently-passed Right-to-Try legislation, Israel-based BrainStorm Cell Therapeutics has reversed course.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
In a first of its kind ruling, the U.S. Food and Drug Administration approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
Nodthera, a U.K.-based startup, snagged $40 million (£28 million) in Series A funding.
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
It’s a big week for the U.S. Food and Drug Administration (FDA) with plenty of upcoming decisions including Achaogen, GW Pharma, Merck and more.
PRESS RELEASES